The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
